feccc57b-a987-4dd7-babf-1a8982bd64cc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.590
- MTORC1_SIGNALING+0.560
- G2M_CHECKPOINT+0.540
- PROTEIN_SECRETION+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.430
- MYC_TARGETS_V2+0.420
- GLYCOLYSIS+0.400
- OXIDATIVE_PHOSPHORYLATION+0.360
- ANDROGEN_RESPONSE+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.420
- ANGIOGENESIS-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- APICAL_JUNCTION-0.280
- MYOGENESIS-0.270
- KRAS_SIGNALING_DN-0.200
- COAGULATION-0.180
- INTERFERON_ALPHA_RESPONSE-0.180
- UV_RESPONSE_DN-0.150
- APICAL_SURFACE-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.900 |
| 2 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.871 |
| 3 | TCGA-46-3765-01A-01R-0980-07 | — | cohortSQ2 | 0.870 |
| 4 | 8027196b-a80b-4759-872d-b72c98905451 | — | — | 0.861 |
| 5 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.859 |
| 6 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.852 |
| 7 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.850 |
| 8 | SRR6013495 | — | cohortA1 | 0.848 |
| 9 | BS_M84H3KXA | Med | Medulloblastoma | 0.844 |
| 10 | SRR1516095 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |